⭐ The authority on professional skin care for over 50 years - Subscribe today! Subscribe Now

FDA recently announced that it had granted a first-ever approval of a combination treatment for melanoma

Please login to like posts.

📖 1 min read

The United States Food and Drug Administration (FDA) recently announced that it had granted a first-ever approval of a combination treatment for melanoma, the most deadly type of skin cancer. The agency approved the combination of GlaxoSmithKline’s genetically-targeted dabrafenib (Tafinlar™) and trametinib (Mekinist™) for patients with metastatic or unresectable melanoma whose tumors possess either the BRAF V600E or V600K genetic mutations.

0 Comments

No comments yet. Be the first to comment!

Wait! Before You Go

Check out these exclusive offers you might be interested in